Zealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's Jared Holz

Zealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's Jared HolzПодробнее

Eli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared HolzПодробнее

New developments in weight-loss drugs: Novo Nordisk, Eli Lilly & Pfizer advance studiesПодробнее

Mizuho's Holz on weight loss drugs: Lilly and Novo Nordisk are in excellent shape fundamentallyПодробнее

Obesity drug supply-demand imbalance is working in Novo Nordisk's favor: Mizuho's Jared HolzПодробнее

Eli Lilly's DTC obesity drug push 'not necessarily an industry game changer': Mizuho's Jared HolzПодробнее

People are 'scratching and clawing' for negative narrative around obesity drugs: Mizuho's Jared HolzПодробнее

Barclays: Novo Nordisk and Eli Lilly have first-move advantage in the obesity drug raceПодробнее

Obesity drug enthusiasm can continue in 2024: Mizuho's Jared HolzПодробнее

Novo Nordisk shares pop after key trial data shows Wegovy cuts risk of heart attack or stroke by 20%Подробнее

Former FDA commissioner: Expect more competition in Eli Lilly and Novo Nordisk's weight-loss drugsПодробнее

Novo Nordisk, Eli Lilly stocks see boost on obesity drugsПодробнее

Eli Lilly and Novo can 'coexist for awhile' in the weight-loss drug space, says BMO's Evan SeigermanПодробнее

Obesity weight loss market will remain a duopoly between Novo Nordisk and Eli Lilly: BofA’S MeachamПодробнее

Eli Lilly to Boost Obesity Drug Supply With Germany FactoryПодробнее

Eli Lilly CEO talks expanding innovation past obesity drugsПодробнее

Jim Cramer weighs the market impact of Eli Lilly and Novo Nordisk's weight loss drugsПодробнее

Eli Lilly's obesity drug will be a tailwind for the stock, says BMO's Evan SeigermanПодробнее

Eli Lilly CEO on Fighting Obesity, Developing New DrugsПодробнее

Eli Lilly has a lot of innovation that goes beyond obesity drugs: analystПодробнее